Role of Somatic mtDNA Mutations in Neurodegeneration
Project Number1R01ES011343-01
Former Number1R01NS041760-01
Contact PI/Project LeaderKHRAPKO, KONSTANTIN
Awardee OrganizationBETH ISRAEL DEACONESS MEDICAL CENTER
Description
Abstract Text
DESCRIPTION (Adapted from the abstract provided by the applicant): The
long-term goal of the proposed research is to study the mechanisms responsible
for the slow progression of late-onset neurodegenerative diseases. The
understanding of these mechanisms may help to find ways to make these processes
even slower, thus moving the onset of these debilitating diseases outside the
normal human lifespan. Specifically, we propose to test the hypothesis that
accumulation of somatic mutations in mtDNA of critical cell types in the brain
is one of the conditions necessary for the progression of at least some
neurodegenerative processes. One of the possibilities is that once the fraction
of mutated mtDNA in specific cells exceeds a certain threshold, these cells
become sensitive to biochemical insults associated with some diseases. This
hypothesis has arisen from the preliminary finding that individual pigmented
neurons in substantia nigra accumulate very high levels of mtDNA deletions,
which are highly likely to compromise cell's resistance to various stresses.
Moreover, there are indications that cells with a heavy mutational load are the
first to die in Parkinson's brain. It is also possible that progression of the
disease accelerates accumulation of mutations thus creating a positive
feedback. The efforts will be focused first on Parkinson's Disease (PD)
patients and pigmented neurons of substantia nigra. Then research will be
extended to Alzheimer's Disease (AD), Huntington's Disease (HD) and the various
corresponding brain areas and critical cell types. The Specific Aims of the
proposal are: 1) To develop and optimize the arsenal of methods necessary for
the precise quantification and characterization of mtDNA mutations in single
cells of the brain. These methods will include laser capture micro-dissection
for single cell isolation, amplification of full-length mitochondrial genomes
from single cells, single cell competitive PCR, and single cell limiting
dilution PCR. 2) To identify brain areas and cell types in which mtDNA
mutations are most likely to contribute to neurodegeneration. This will be done
by measuring mutation load in individual cells of substantia nigra, cortex and
putamen that are known to be rich in mtDNA deletions and are critical for PD,
AD, and HD, respectively. 3) To test the hypothesis that clonal expansions of
mtDNA mutations in individual cells contribute to mitochondrial defects and to
neurodegeneration and death of neurons. This will be done by comparing the
mutational load of cells that stained positive for various markers of
mitochondrial dysfunction, cell degeneration and death to non-staining control
cells. We will also study the distribution the mutations as a function of age
and the presence and severity of the disease.
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
071723621
UEI
C1CPANL3EWK4
Project Start Date
01-July-2001
Project End Date
31-May-2006
Budget Start Date
01-July-2001
Budget End Date
31-May-2002
Project Funding Information for 2001
Total Funding
$266,752
Direct Costs
$175,000
Indirect Costs
$91,752
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Environmental Health Sciences
$266,752
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01ES011343-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01ES011343-01
Patents
No Patents information available for 1R01ES011343-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01ES011343-01
Clinical Studies
No Clinical Studies information available for 1R01ES011343-01
News and More
Related News Releases
No news release information available for 1R01ES011343-01
History
No Historical information available for 1R01ES011343-01
Similar Projects
No Similar Projects information available for 1R01ES011343-01